Komrokji R, al Ali N, Chan O, Sweet K, Kuykendall A, Lancet J, Padron E, Sallman DA. <i>IDH</i&gt; mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy. haematol [Internet]. 2023Apr.1 [cited 2024Nov.27];108(4):1168-72. Available from: https://haematologica.org/article/view/haematol.2022.281607